July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Karen Knudsen: A huge thank you to the 74 CEOs who participated in our one-day Fit2BeCancerFree CEO Challenge
Apr 26, 2024, 08:37

Karen Knudsen: A huge thank you to the 74 CEOs who participated in our one-day Fit2BeCancerFree CEO Challenge

Karen Knudsen shared on X/Twitter:

A huge thank you to the 74 CEOs who participated in our one-day Fit2BeCancerFree CEO Challenge. In total, they accumulated a whopping 3,131,916 steps! Congratulations to our step leader Ethan Brown of Beyond Meat who racked up a record 189,914 steps.

In second place, Juan Ignacio Diddi of Bristol Myers Squibb walked an incredible 161,205 steps yesterday. Congrats, Juan!

Craig Robinson of FlowPlay was our third-place finisher, totaling 115,884 steps in 24 hours. Well done, Craig!

Karen Knudsen/X

And of course, shout out to Steve O’Loughlin, our ‘Most Socially Active’ award winner for the Fit2BeCancerFree CEO Challenge! Remember, the employee challenge continues through May 9. Check out the leaderboard and find out how you can support here.”

Karen Knudsen/X

Source: Karen Knudsen/X

Karen Knudsen is the CEO of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health. She also served as president for the Association of American Cancer Institutes (AACI), representing the 102 leading cancer centers in North America, and on the board of directors of the American Association for Cancer Research (AACR).

Dr. Knudsen currently holds leadership roles with some of the most important cancer entities in the United States. She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.